In 2022, Aref et al. named CXCL-10 as a novel biomarker for B-ALL’s response to induction chemotherapy, as their research demonstrated that bone marrow plasma levels of CCL-2, CXCL-9, and CXCL-10 at day 0 were significantly higher as compared to their levels at day 15. The gene discussed is CXCL10; the disease is precursor B-cell acute lymphoblastic leukemia.